A clinical-stage biopharmaceutical company focused on developing therapies for rare and orphan diseases, with programs targeting neurological and cardiovascular conditions. Its pipeline includes drug candidates such as GTX-104, an intravenous formulation of nimodipine being studied for subarachnoid ...
1 member of Congress has disclosed 1 trade in Acasti Pharma Inc. (ACST), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2021-03-16 | Mark Dr Green | buy | $1K – $15K |